These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22890763)

  • 1. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
    Li JZ; Gallien S; Do TD; Martin JN; Deeks S; Kuritzkes DR; Hatano H
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5998-6000. PubMed ID: 22890763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
    Kantor R; DeLong A; Schreier L; Reitsma M; Kemboi E; Orido M; Obonge S; Boinett R; Rono M; Emonyi W; Brooks K; Coetzer M; Buziba N; Hogan J; Diero L
    AIDS; 2018 Nov; 32(17):2485-2496. PubMed ID: 30134290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
    Vardhanabhuti S; Taiwo B; Kuritzkes DR; Eron JJ; Bosch RJ
    Antivir Ther; 2015; 20(1):73-6. PubMed ID: 24699164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.
    Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S
    Viruses; 2024 May; 16(5):. PubMed ID: 38793602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.
    Tobin NH; Learn GH; Holte SE; Wang Y; Melvin AJ; McKernan JL; Pawluk DM; Mohan KM; Lewis PF; Mullins JI; Frenkel LM
    J Virol; 2005 Aug; 79(15):9625-34. PubMed ID: 16014925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
    Zhang T; Ding H; An M; Wang X; Tian W; Zhao B; Han X
    BMC Infect Dis; 2020 Feb; 20(1):147. PubMed ID: 32066392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
    Delaugerre C; Gallien S; Flandre P; Mathez D; Amarsy R; Ferret S; Timsit J; Molina JM; de Truchis P
    PLoS One; 2012; 7(5):e36673. PubMed ID: 22590588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.
    Ryscavage P; Kelly S; Li JZ; Harrigan PR; Taiwo B
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3585-98. PubMed ID: 24733471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.
    Gonzalez-Serna A; Swenson LC; Watson B; Zhang W; Nohpal A; Auyeung K; Montaner JS; Harrigan PR
    Clin Microbiol Infect; 2016 Dec; 22(12):1004.e9-1004.e16. PubMed ID: 27585940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
    Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
    Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.
    Maggiolo F; Callegaro A; Cologni G; Bernardini C; Velenti D; Gregis G; Quinzan G; Soavi L; Iannotti N; Malfatto E; Leone S
    J Acquir Immune Defic Syndr; 2012 Aug; 60(5):473-82. PubMed ID: 22481602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.
    Mackie NE; Phillips AN; Kaye S; Booth C; Geretti AM
    J Infect Dis; 2010 May; 201(9):1303-7. PubMed ID: 20350161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis.
    Taramasso L; Magnasco L; Bruzzone B; Caligiuri P; Bozzi G; Mora S; Balletto E; Tatarelli P; Giacomini M; Di Biagio A
    J Clin Virol; 2020 Feb; 123():104255. PubMed ID: 31927152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.
    Liu J; Li C; Sun Y; Fu C; Wei S; Zhang X; Ma J; Zhao Q; Huo Y
    Sci Rep; 2024 May; 14(1):10620. PubMed ID: 38724547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.
    Fleming J; Mathews WC; Rutstein RM; Aberg J; Somboonwit C; Cheever LW; Berry SA; Gebo KA; Moore RD;
    AIDS; 2019 Nov; 33(13):2005-2012. PubMed ID: 31306175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
    El-Khatib Z; Ekstrom AM; Ledwaba J; Mohapi L; Laher F; Karstaedt A; Charalambous S; Petzold M; Katzenstein D; Morris L
    AIDS; 2010 Jul; 24(11):1679-87. PubMed ID: 20453629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.